RxDoctor Payments Data

Jesse Powell, PA

Physician Assistant · Minneapolis, MNNPI 1134389646

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.2%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Gilead accounts for 99.9% of it on its own, with 2 other manufacturers making up the rest. Among physician assistant clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$30,389in general payments, 2019–2025

Across 68 payments — averaging $446.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$30K
  • Ipsen Biopharmaceuticals, Inc$26
  • AbbVie$17
$2,642in research payments, 2019–2025

Across 16 payments — averaging $165.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$3K

What the payments were for

  • Consulting fees$5,93020%
  • Speaking & faculty fees$15,27050%
  • Travel & lodging$8,04426%
  • Food & beverage$1,1454%

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead66$30,346
Ipsen Biopharmaceuticals, Inc1$26
AbbVie1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,389 in reported general payments places this provider in the 95th percentile of 3,121 physician assistant providers in Minnesota.

See all physician assistant providers in Minnesota

Medicare billing

Part B allowed, 2024
$8,669
Medicare patients
78
Services billed
213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin64$154,963
VemlidyTenofovir Alafenamide25$36,058
Ursodiol86$9,379
LinzessLinaclotide11$8,838
Entecavir82$7,173
Tenofovir Disoproxil Fumarate35$2,250
Omeprazole69$801
Spironolactone61$742
Lactulose14$650
Furosemide55$550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$30,346$36,05825 claims
AbbVieLinzess$17$8,83811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,121 physician assistant providers in Minnesota.

Other physician assistant in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →